Supplementary Material for: Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany between 2015–2021

Introduction: The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 to 2021. Methods: In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period. Results: The incidence of primary advanced or recurrent endometrial cancer in 2021 was 4.77 cases/100 000 persons, with no substantial change over time (4.63 in 2018; 4.93 in 2019; 4.45 in 2020). The point prevalence on 1 January 2022 was 0.023%, with a slight increase in prevalence observed from 1 January 2019 onwards. Among 466 patients with confirmed endometrial cancer, the mean (standard deviation) age was 68.0 (11.6) years; the tumor material from 86 patients (18.5%) underwent immunohistochemistry or polymerase chain reaction testing. Median overall survival was estimated to be 47.5 months (95% CI 35.1 to 70.4) and the 5-year survival probability was 46.2%. The most frequent first-line systemic therapies were carboplatin (45.7%) and paclitaxel (43.1%). Second-line therapy was received by 153 patients (32.8%). Conclusion: The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.

引言：本研究旨在描述德国2015年至2021年间原发性晚期或复发性子宫内膜癌的流行病学特征以及受影响患者的真实世界治疗模式所取得的疗效。方法：本项回顾性队列研究覆盖了2015年1月1日至2021年12月31日的时段，从匿名索赔数据集中提取了接受疾病系统性治疗的原发性晚期或复发性子宫内膜癌患者的数据。评估了截至研究日期的累积发病率和点现患率。对指数日期后的子宫内膜癌相关真实世界治疗模式进行了描述。结果：2021年原发性晚期或复发性子宫内膜癌的发病率为每10万人4.77例，随时间推移变化不显著（2018年为4.63例，2019年为4.93例，2020年为4.45例）。2022年1月1日的点现患率为0.023%，自2019年1月1日起现患率略有上升。在466名确诊为子宫内膜癌的患者中，平均（标准差）年龄为68.0（11.6）岁；86名患者（18.5%）的肿瘤样本进行了免疫组化或聚合酶链反应检测。中位总生存期估计为47.5个月（95%置信区间为35.1至70.4），5年生存概率为46.2%。最常见的一线系统性治疗药物为卡铂（45.7%）和多西他赛（43.1%）。153名患者（32.8%）接受了二线治疗。结论：对德国索赔数据的分析产生了关于晚期或复发性子宫内膜癌的当代流行病学估计。在研究期间，治疗方案与指南推荐相符，而肿瘤检测尚未成为主流实践。